Cargando…

Old drug fluvoxamine, new hope for COVID-19

Detalles Bibliográficos
Autores principales:	Hashimoto, Yaeko, Suzuki, Takuji, Hashimoto, Kenji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8412866/ https://www.ncbi.nlm.nih.gov/pubmed/34476589 http://dx.doi.org/10.1007/s00406-021-01326-z

Ejemplares similares

Mechanisms of action of fluvoxamine for COVID-19: a historical review
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Comments to “Fluvoxamine and long COVID-19: a new role for sigma-1 receptor (S1R) agonists” by Khani and Entezari-Maleki
por: Hashimoto, Yaeko, et al.
Publicado: (2022)

Fluvoxamine, melatonin and COVID-19
por: Anderson, George M.
Publicado: (2021)

Overview of the potential use of fluvoxamine for COVID-19 and long COVID
por: Hashimoto, Kenji
Publicado: (2023)

Heme oxygenase agonists—fluvoxamine, melatonin—are efficacious therapy for Covid-19
por: Hooper, Philip L.
Publicado: (2021)

Repurposing fluvoxamine, and other psychiatric medications, for COVID‐19 and other conditions
por: Lenze, Eric J., et al.
Publicado: (2022)

Efficacy and safety of fluvoxamine for the treatment of COVID-19 patients: A systematic review and meta-analysis
por: Cheema, Huzaifa Ahmad, et al.
Publicado: (2022)

Fluvoxamine for blonanserin-associated akathisia in patients with schizophrenia: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Fluvoxamine monotherapy for psychotic depression: the potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2009)

Sigma-1 receptor agonist fluvoxamine for delirium in patients with Alzheimer's disease
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Emergence of kleptomania during treatment for obsessive compulsive disorder with fluvoxamine
por: Gupta, Parveen Rani
Publicado: (2014)

A meta-analysis regarding fluvoxamine and hospitalization risk of COVID-19 patients: TOGETHER making a difference
por: Marcec, Robert, et al.
Publicado: (2022)

Risk of neuropsychiatric disorders in offspring of COVID-19-infected pregnant women and nutritional intervention
por: Hashimoto, Kenji
Publicado: (2020)

Colchicine for COVID-19: Hype or hope?
por: Kow, Chia Siang, et al.
Publicado: (2022)

Fluvoxamine for aripiprazole-associated akathisia in patients with schizophrenia: a potential role of sigma-1 receptors
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Sigma-1 receptor agonist fluvoxamine for delirium in intensive care units: report of five cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Sigma-1 receptor agonist fluvoxamine for postoperative delirium in older adults: report of three cases
por: Furuse, Tsutomu, et al.
Publicado: (2010)

Roxadustat for SARS-CoV-2 Infection: Old Signaling Raised New Hopes
por: Alkazmi, Luay, et al.
Publicado: (2022)

Roadblocks and COVID-19: Hope and Strict Control
por: Joob, Beuy, et al.
Publicado: (2020)

Fluvoxamine for the treatment of COVID-19
por: Dodds, Michael G, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Boulware, David R, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Kim, Hyun, et al.
Publicado: (2022)

Fluvoxamine for the treatment of COVID-19
por: Marzolini, Catia, et al.
Publicado: (2022)

Benefical Effects of Sigma-1 Agonist Fluvoxamine for Tardive Dyskinesia and Tardive Akathisia in Patients with Schizophrenia: Report of Three Cases
por: Albayrak, Yakup, et al.
Publicado: (2013)

Fluvoxamine Plays an Integral Role in the Alteration of Sexual Behavioral Pattern more in Females than Males
por: Santra, Ranjita
Publicado: (2012)

The opposite effects of fluvoxamine and sertraline in the treatment of psychotic major depression: a case report
por: Kishimoto, Akira, et al.
Publicado: (2010)

There is no reasonable evidence to support efficacy of fluvoxamine in prevention of disease deterioration in COVID-19 outpatients: A comment on two recent meta-analyses advocating its use
por: Trkulja, Vladimir
Publicado: (2022)

Comment on: “Fluvoxamine for the Early Treatment of SARS-CoV-2 Infection: A Review of Current Evidence”
por: Mazza, Mario Gennaro, et al.
Publicado: (2022)

Fluvoxamine for symptomatic outpatients with COVID-19
por: Wu, Peter E., et al.
Publicado: (2022)

Fluvoxamine
por: DeVane, C Lindsay
Publicado: (2005)

Echinocandins: A ray of hope in antifungal drug therapy
por: Grover, Neeta D.
Publicado: (2010)

Macroscopic hematuria in two children with IgA nephropathy remission following Pfizer COVID-19 vaccination
por: Udagawa, Tomohiro, et al.
Publicado: (2022)

Undergraduate research in India hoping for a new dawn
por: Chatterjee, Krishnarpan, et al.
Publicado: (2016)

Fluvoxamine for the treatment of COVID-19 – Author's reply
por: Reis, Gilmar, et al.
Publicado: (2022)

Fluvoxamine may prevent onset of psychosis: a case report of a patient at ultra-high risk of psychotic disorder
por: Tadokoro, Shigenori, et al.
Publicado: (2011)

Role of povidone-iodine gargles in COVID-19 pandemic and a ray of hope for future
por: Garg, Pankaj
Publicado: (2021)

Authors’ Reply to Mazza et al.: “Fluvoxamine for the Early Treatment of SARS‑CoV‑2 Infection: A Review of Current Evidence”
por: Lenze, Eric J., et al.
Publicado: (2022)

Tricyclic Antidepressants: Old Drugs-New Applications
por: Solakovic, Nedim
Publicado: (2011)

A BDNF Val66Met Polymorphism and Ketamine-induced Rapid Antidepressant Action
por: Hashimoto, Kenji
Publicado: (2012)

The R-Stereoisomer of Ketamine as an Alternative for Ketamine for Treatment-resistant Major Depression
por: Hashimoto, Kenji
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v81b95djlln4og5b6ifg4pohlh